# Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

> **NCT00138242** · PHASE2 · COMPLETED · sponsor: **Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** carboplatin
- **DRUG:** docetaxel
- **PROCEDURE:** adjuvant therapy

## Key facts

- **NCT ID:** NCT00138242
- **Lead sponsor:** Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** —
- **Final completion:** 2006-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2013-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00138242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00138242, "Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00138242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*